CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
about
Post-exposure prophylaxis for SIV revisited: animal model for HIV preventionInefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivoZika Virus Tissue and Blood Compartmentalization in Acute Infection of Rhesus MacaquesBiological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaquesCD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells.Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Experimental depletion of CD8+ cells in acutely SIVagm-infected African Green Monkeys results in increased viral replication.Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS.Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11.AIDS vaccines and preexposure prophylaxis: is synergy possible?Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques.Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.Identifying the Conditions Under Which Antibodies Protect Against Infection by Equine Infectious Anemia Virus.Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine.A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.Tackling HIV and AIDS: contributions by non-human primate models.CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART).Control of M184V HIV-1 mutants by CD8 T-cell responses.
P2860
Q21245029-D55D04C7-2473-4224-AC6A-047522F3C94FQ25255777-FDB75F55-9B91-4A8B-B0D3-D0213AA2915BQ28598954-5795AF8E-084F-432A-92ED-9B3AA715A37FQ28775900-9D2EE466-31D3-4EED-8F9A-5E2EE84166B5Q33618007-ADC4A348-3267-46E1-B8E3-F4D907153FC3Q33653655-457FF258-3AF2-43AC-8259-EF1817500C93Q33888012-FA84F195-13AB-4BE5-95DB-1556E97E868DQ33919945-61B4B76F-2369-4636-B2AC-DC09D448A409Q34716901-DF114CA0-D8AA-410C-9E79-B18309BC309DQ34767799-2A53D5D0-5935-4DC1-9159-58BC2B2956E5Q35003539-3DA42D98-F32D-4ADE-83D8-A3A76E5FB274Q35024276-F9C19749-218F-48DD-88AF-9FC98DE2FF1FQ35115071-A54454DA-3F9C-4E07-9AE7-84A1E310C887Q35752812-5D46599F-D8C8-4CFB-A869-37A1E2CCF4E3Q35826784-E6D16AE6-EAF2-4432-998F-4F0C2B7A0A74Q35963420-7A72BA8B-EEC3-4F7C-A065-BCCAC1D7B983Q36164175-1A7B6E6A-4D1B-4126-9A20-A95D985B95E0Q36172455-FD5CB765-11DC-4C8A-85BA-92CB6F896CD8Q36281109-0543803C-6868-4DC4-868B-8874AA4D1981Q36870864-49B552CE-3E7D-41BA-A076-CC1A4753FF06Q37156717-956F975D-9A3C-4E87-9A98-7B95C9226D24Q37547093-5C84E6F1-7D67-4BF4-BF0C-1DD8E0311E14Q40191155-4BC628B4-0DAE-489A-BBC2-8B891E2D7C3AQ40532397-0749CFB7-51B5-460E-87D5-56EFD9EAAAE6Q40902737-71EFEBF6-FA3B-4D2E-81AA-151FE81671C6Q43011767-940B8275-1E35-438F-91F1-02E036822932Q50357334-EE32E4C1-1E78-4CDB-A130-1A71DB10BA0DQ54332318-2F24EBCA-664C-4E0C-BFB7-502AC5472981
P2860
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@en
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@nl
type
label
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@en
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@nl
prefLabel
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@en
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@nl
P2093
P2860
P1433
P1476
CD8+-cell-mediated suppression ...... us during tenofovir treatment.
@en
P2093
Casey Wingfield
Donald L Sodora
Jonathan R Lawson
Koen K A Van Rompay
Marta L Marthas
Norbert Bischofberger
Raman P Singh
P2860
P304
P356
10.1128/JVI.78.10.5324-5337.2004
P407
P50
P577
2004-05-01T00:00:00Z